Literature DB >> 11315565

Hydrolysis of the tumor-inhibiting ruthenium(III) complexes HIm trans-[RuCl4(im)2] and HInd trans-[RuCl4(ind)2] investigated by means of HPCE and HPLC-MS.

A Küng1, T Pieper, R Wissiack, E Rosenberg, B K Keppler.   

Abstract

High performance capillary electrophoresis (HPCE) as well as high performance liquid chromatography-mass spectrometry (HPLC-MS) have been applied to the separation, identification and quantification of the tumor-inhibiting ruthenium compounds HIm trans-[RuCl4(im)2] (im = imidazole) and HInd trans-[RuCl4(ind)2] (ind = indazole) and their hydrolysis products. The half-lives for the hydrolytic decomposition of the Ru(III) compounds were determined by monitoring the relative decrease of the original complex anion under different conditions by means of capillary electrophoresis. The decomposition follows pseudo-first-order kinetics. The rate constants in water at 25 degrees C are 1.102 +/- 0.091 x 10(-5) s-1 for HIm trans-[RuCl4(im)2] and 0.395 +/- 0.014 x 10(-5) s-1 for HInd trans-[RuCl4(ind)2]. About 8% of HIm trans-[RuCl4(im)2] but only about 2% of HInd trans-[RuCl4(ind)2] were hydrolyzed after 1 h at room temperature. Whereas the hydrolysis rate of the imidazole complex is independent of the pH value, the indazole complex hydrolyzes much faster at higher pH. The half-life of HInd trans-[RuCl4(ind)2] in phosphate buffer at pH 6.0 and 37 degrees C is 5.4 h, whereas it is less than 0.5 h at pH 7.4. In contrast to the imidazole complex, where no dependence on the buffer system was observed, hydrolysis of the indazole complex is even faster if a buffer containing hydrogen carbonate is used. The formation of [RuCl2(H2O)2(im)2]+ could be demonstrated by HPLC-MS measurements. In the case of the indazole complex, a release of the indazole ligands results in the formation of [RuCl4(H2O)2]-.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11315565     DOI: 10.1007/s007750000203

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  5 in total

1.  Characterization of the binding sites of the anticancer ruthenium(III) complexes KP1019 and KP1339 on human serum albumin via competition studies.

Authors:  Orsolya Dömötör; Christian G Hartinger; Anna K Bytzek; Tamás Kiss; Bernhard K Keppler; Eva A Enyedy
Journal:  J Biol Inorg Chem       Date:  2012-10-18       Impact factor: 3.358

2.  Serum-protein interactions with anticancer Ru(III) complexes KP1019 and KP418 characterized by EPR.

Authors:  Naniye Cetinbas; Michael I Webb; Joshua A Dubland; Charles J Walsby
Journal:  J Biol Inorg Chem       Date:  2009-08-26       Impact factor: 3.358

3.  Facile synthesis of indole heterocyclic compounds based micellar nano anti-cancer drugs.

Authors:  Imran Ali; Sofi Danish Mukhtar; Ming Fa Hsieh; Zeid A Alothman; Abdulrahman Alwarthan
Journal:  RSC Adv       Date:  2018-11-13       Impact factor: 4.036

4.  Antiangiogenic properties of selected ruthenium(III) complexes that are nitric oxide scavengers.

Authors:  L Morbidelli; S Donnini; S Filippi; L Messori; F Piccioli; P Orioli; G Sava; M Ziche
Journal:  Br J Cancer       Date:  2003-05-06       Impact factor: 7.640

5.  X-ray absorption near edge structure spectroscopy to resolve the in vivo chemistry of the redox-active indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019).

Authors:  Alfred A Hummer; Petra Heffeter; Walter Berger; Martin Filipits; David Batchelor; Gabriel E Büchel; Michael A Jakupec; Bernhard K Keppler; Annette Rompel
Journal:  J Med Chem       Date:  2013-01-31       Impact factor: 7.446

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.